Skip to search formSkip to main contentSkip to account menu

Anti-CEA BiTE Monoclonal Antibody MEDI-565, Human

Known as: MEDI-565 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
320 Background: MEDI-565, a bispecific single-chain antibody, targets human CEA on tumor cells and the CD3 epsilon subunit of the… 
2015
2015
TPS3097 Background: The bispecific CD19-directed CD3 T-cell engager (BiTE(R)) blinatumomab was recently approved by FDA as single… 
Highly Cited
2014
Highly Cited
2014
Individual or combinations of somatic mutations found in genes from colorectal cancers can redirect the effects of chemotherapy… 
2012
2012
MEDI-565 (also known as MT111) is a bispecific T-cell engager (BiTE®) antibody in development for the treatment of patients with… 
2012
2012
Colorectal cancer (CRC) cells can harbor somatic mutations with strong impact on cancer cell signaling that limit the… 
Highly Cited
2010
Highly Cited
2010
Background:Novel technologies to redirect T-cell killing against cancer cells are emerging. We hypothesised that metastatic human… 
2010
2010
MEDI-565 (MT111) is a novel bispecific single-chain antibody of the BiTE (Bi-specific T-cell engager) class that transiently… 
2010
2010
Carcinoembryonic antigen (CEA; CD66e, CEACAM5) is a well-characterized tumor-associated antigen that is frequently and uniformly… 
2010
2010
MEDI-565 (MT111) is a novel bispecific single-chain antibody of the BiTE (Bispecific T cell engager) class that transiently links…